Chun R, Knapp D W, Widmer W R, DeNicola D B, Glickman N W, Kuczek T, Degortari A, Han C M
Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, IN, USA.
J Vet Intern Med. 1997 Sep-Oct;11(5):279-83. doi: 10.1111/j.1939-1676.1997.tb00465.x.
Fourteen dogs with histologically-confirmed transitional cell carcinoma (TCC) of the urinary bladder were treated with 300 mg/m2 carboplatin every 3 weeks. Response to therapy was assessed with abdominal radiography, double contrast cystography, urinary bladder ultrasonography and thoracic radiography before therapy and at 6-week intervals during therapy. Dogs were monitored for hematologic toxicity with a CBC and platelet count performed immediately before and 10 to 14 days after carboplatin treatment. Tumor responses included progressive disease in 11 dogs and stable disease in 1 dog. Two dogs were euthanized due to carboplatin toxicity before assessment of tumor response. Toxicity included thrombocytopenia with or without neutropenia in 7 dogs and gastrointestinal toxicity in 6 dogs. Carboplatin therapy was not beneficial in the treatment of TCC in the 14 dogs in this study.
十四只经组织学确诊为膀胱移行细胞癌（TCC）的犬，每3周接受300mg/m²卡铂治疗。在治疗前以及治疗期间每隔6周，通过腹部X线摄影、双重对比膀胱造影、膀胱超声检查和胸部X线摄影评估治疗反应。在卡铂治疗前即刻以及治疗后10至14天进行全血细胞计数（CBC）和血小板计数，监测犬的血液学毒性。肿瘤反应包括11只犬病情进展，1只犬病情稳定。在评估肿瘤反应前，2只犬因卡铂毒性而实施安乐死。毒性反应包括7只犬出现伴有或不伴有中性粒细胞减少的血小板减少症，6只犬出现胃肠道毒性。在本研究的14只犬中，卡铂治疗对TCC治疗并无益处。
